-
It's a tough time to be a home health manager. For years, you've implemented new processes and new services designed to strengthen your agency, but it's hard to fight an economic environment that is forcing all industries to reevaluate how they conduct business.
-
Terumo Heart (Ann Arbor, Michigan) moved another step closer in its quest to release its DuraHeart Left Ventricular Assist System on the market, after the Institutional Review Board of the University of Michigan voted in late June to move forward with the device's pivotal trial for a bridge-to-transplant indication.
-
AGA Medical Holdings; Boston Scientific; Cambridge Heart; FlowCardia; MedCath; Quintiles Transnational; Signalife; Stereotaxis; Xtent
-
Despite the fact that it is the only FDA-approved drug to treat ischemic stroke, Activase, also known as tissue plasminogen activator (tPA), a product from Genentech (South San Francisco, California) is not used in the majority of cases for which it is approved.
-
SAN FRANCISCO Remote monitoring of implanted cardiac devices is hot at least at the level of discussion during scientific conferences, if not at the level of reimbursement of such services. But one step at a time: This technology clearly is adding more evidence concerning efficacy, if not clear cost-effectiveness.
-
BARCELONA, Spain EuroPCR, a prestigious meeting organized by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), an association of the European Society of Cardiology (Sophia Antipolis, France) and a group focused on interventional devices used for diagnosis and treatment of cardiovascular disease, is the leading interventional meeting in Europe and an important forum for introducing new devices.
-
After more than two years of clinical data linking drug-eluting stents (DES) with an increased risk of stent thrombosis compared to their bare-metal cousins, a study in the Journal of the American Medical Association (JAMA) may shed some positive light on the DES space.
-
Cook Medical; HealthTrust Purchasing Group; Freescale Semiconductor; Monebo Technologies; HemCon Medical Technologies; SanguiBioTech; LifeScan; ResMed; Johnson & Johnson; IDev Technologies; YMed; Positron; Disease Management; NuView Radiopharmaceuticals
-
In a move that could help offset its $458 million 4Q07 Gudiant-related losses, Boston Scientific (Natick, Massachusetts) reported last month that it had signed a definitive agreement to sell its investments in a portfolio of companies, subject to certain closing and other conditions, to Saints Capital (San Francisco), a secondary direct-investment firm.
-
Applera; Celera; Berkeley HeartLab; Abbott Laboratories; Applied Biosystems; Invitrogen; Escalon Medical; Drew Scientific; JAS Diagnostics; Kardia Health Systems; Freeland Systems; Pediatrix Medical Group
